
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
Peter T. Scardino, MD, FACS, discusses an analysis presented at the 2014 AUA Annual Meeting: Validation of a 46-gene cell cycle progression (CCP) RNA signature for predicting prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort.
Peter T. Scardino, MD, FACS, Chair, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses an analysis presented at the 2014 AUA Annual Meeting: Validation of a 46-gene cell cycle progression (CCP) RNA signature for predicting prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort.






